Latest News by Industry
![Mersana Therapeutics, Inc. [MRSN] reports annual net loss of $171,670,000.0](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FMRSN.png&w=1200&q=75)
Mersana Therapeutics, Inc. [MRSN] has reported a net loss of $171,670,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $36.9 million
Based in CAMBRIDGE, Massachusetts, Mersana Therapeutics, Inc. operates in the MANUFACTURING sector.
In the Consolidated Statements of Operations and Comprehensive Loss for the 12 Months Ended December 31 of the years 2023, 2022, and 2021, the following financial data was reported:
Collaboration revenue amounted to $36.855 million in 2023, increasing from $26.581 million in 2022 and $43,000 in 2021.
Operating expenses were as follows: Research and development costs were $148.269 million in 2023, down from $173.385 million in 2022 and higher than $132.013 million in 2021. General and administrative expenses stood at $59.543 million in 2023, compared to $56.963 million in 2022 and $36.888 million in 2021. Additionally, restructuring expenses were $8.713 million in 2023.
Other income and expenses showed the following: Interest income was $12.073 million in 2023, $2.883 million in 2022, and $65,000 in 2021. Interest expenses were ($4.073) million in 2023, ($3.328) million in 2022, and ($1.267) million in 2021. The total other income (expense), net was $8.000 million in 2023, a significant improvement from (-$0.445) million in 2022 and (-$1.202) million in 2021.
The net loss for the year 2023 was ($171.670) million, decreased from ($204.212) million in 2022 and almost similar to ($170.060) million in 2021.
The net loss per share attributable to common stockholders for basic and diluted shares were both ($1.48) in 2023. This compares to ($2.18) in 2022 and ($2.41) in 2021. The weighted-average number of shares of common stock used in calculating the net loss per share remained consistent at 116,112,891 for both basic and diluted shares across the three years.
Also Read: